Complementary discoveries have the potential to enhance treatment options for antibiotic-resistant infections. Researchers at ...
XMRV was originally described in 2006 in the tumour tissue of patients with a familial form of prostate cancer associated with mutations that impair the function of the antiviral defence protein ...